Editas Medicine Stock Filter Stocks by Fundamentals
| EDIT Stock | USD 2.38 0.06 2.46% |
Editas Medicine fundamentals help investors to digest information that contributes to Editas Medicine's financial success or failures. It also enables traders to predict the movement of Editas Stock. The fundamental analysis module provides a way to measure Editas Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Editas Medicine stock.
Editas | Shares Owned by Institutions |
Editas Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.5B | 4.1B | 1.8B | 609.1M | 769.5M | 1.0B | |
| Enterprise Value | 1.3B | 4.0B | 1.6B | 511.5M | 682.4M | 921.9M |
Editas Medicine ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Editas Medicine's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Editas Medicine's managers, analysts, and investors.Environmental | Governance | Social |
Editas Medicine Institutional Holders
Institutional Holdings refers to the ownership stake in Editas Medicine that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Editas Medicine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Editas Medicine's value.| Shares | Goldman Sachs Group Inc | 2024-06-30 | 1.2 M | Woodline Partners Lp | 2024-06-30 | 970.5 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 897.5 K | Two Sigma Advisers, Llc | 2024-06-30 | 856.5 K | Jpmorgan Chase & Co | 2024-06-30 | 799.2 K | Northern Trust Corp | 2024-09-30 | 703.8 K | Squarepoint Ops Llc | 2024-06-30 | 694.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 617.3 K | Raymond James & Associates | 2024-09-30 | 561.4 K | Blackrock Inc | 2024-06-30 | 7.8 M | Vanguard Group Inc | 2024-09-30 | 6.7 M |
Editas Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (30.14 M) | ||||
| Shares Outstanding | 82.55 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 70.13 % | ||||
| Number Of Shares Shorted | 17.24 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 3.18 X | ||||
| Revenue | 78.12 M | ||||
| Gross Profit | (155.25 M) | ||||
| EBITDA | (163.12 M) | ||||
| Net Income | (153.22 M) | ||||
| Cash And Equivalents | 452.56 M | ||||
| Cash Per Share | 6.59 X | ||||
| Total Debt | 36.54 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 12.67 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (132.18 M) | ||||
| Short Ratio | 8.76 X | ||||
| Earnings Per Share | (2.54) X | ||||
| Target Price | 8.21 | ||||
| Number Of Employees | 265 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 196.46 M | ||||
| Total Asset | 499.15 M | ||||
| Retained Earnings | (1.23 B) | ||||
| Working Capital | 277.61 M | ||||
| Current Asset | 144.99 M | ||||
| Current Liabilities | 6.92 M | ||||
| Net Asset | 499.15 M |
About Editas Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.